Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647650 | 0.88 | ALDH1A1 (0.42) | TDP1KMT2APOLBL3MBTL1SLC6A2 | |
| SCHEMBL31647804 | 0.88 | FOLH1 (0.39) | POLBKDM4E | |
| SCHEMBL29662410 | 0.84 | PIN1 (0.39) | PIN1MMP8TDP1MEN1NPC1 | |
| SCHEMBL8892070 | 0.81 | FFAR1 (0.37) | — | |
| SCHEMBL25591718 | 0.81 | PIN1 (0.45) | PIN1MMP8TDP1MEN1NPC1 | |
| SCHEMBL10757035 | 0.81 | PIN1 (0.45) | PIN1MMP8TDP1MEN1NPC1 | |
| SCHEMBL10757041 | 0.81 | PIN1 (0.45) | PIN1MMP8TDP1MEN1NPC1 | |
| SCHEMBL1806312 | 0.81 | KMT2A (0.39) | MEN1KMT2ALMNAKDM4E | |
| SCHEMBL31647497 | 0.80 | TBXAS1 (0.39) | NPC1 | |
| SCHEMBL31647824 | 0.80 | ALDH1A1 (0.43) | TDP1MEN1KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501961-B2 | HIV protease inhibitors and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118330-A1 | HIV PROTEASE INHIBITORS AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118330-A1 | HIV PROTEASE INHIBITORS AND METHODS FOR USING | SERPINB1, PREP, PEPD | PIN1 444/4885MMP8 60/4885TDP1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.